Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For The Treatment Of Friedreich's Ataxia
MGTX•IND clearance and trial timing
Aug. 11 (Reuters) - MeiraGTx Holdings PLC (MGTX.O):
- Graviton Bioscience announces clearance of investigational new drug (IND) for GV101 for the treatment of Friedreich's ataxia
- MeiraGTx - enrollment for phase 2 GV101 trial expected to begin in Q1 2027
